Power Efficacy with no increased risk of hypoglycaemia. Lower incidence of Genital Tract Infection Other safety No increased risk of hypoglycaemia¹ zoom Despite high efficacy, no increased risk of hypoglycaemia1 FDC: Fixed-dose combination. EMPA: Empagliflozin. LINA: Linagliptin. Reference: DeFronzo RA, et al. Adv Ther. 2018;35(7):1009-22. Why Glyxambi®? Why Glyxambi®? Guidelines Efficacy Pleiotropic benefits Cardiovascular evidence Renal evidence Other safety Differentiation v/s other FDC Efficacy vs. Glimepiride Other benefits vs. Glimepiride Lower incidence of GTI vs. Empagliflozin alone1 Zoom Lower incidence of GTI vs. Empagliflozin alone1 FDC: Fixed-dose combination. EMPA: Empagliflozin. LINA: Linagliptin. GTI: Genital tract infection. Reference: DeFronzo RA, et al. Adv Ther. 2018;35(7):1009-22.